Search

Your search keyword '"Weaver, Richard J"' showing total 189 results

Search Constraints

Start Over You searched for: Author "Weaver, Richard J" Remove constraint Author: "Weaver, Richard J"
189 results on '"Weaver, Richard J"'

Search Results

2. Acceptable intakes (AIs) for 11 small molecule N-nitrosamines (NAs)

4. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models

6. A ligand-induced structural change in fatty acid–binding protein 1 is associated with potentiation of peroxisome proliferator–activated receptor α agonists

9. A systems approach reveals species differences in hepatic stress response capacity

10. A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity

15. Stem cell–derived models to improve mechanistic understanding and prediction of human drug‐induced liver injury

16. A systems approach reveals species differences in hepatic stress response capacity

19. Challenges and approaches for the development of safer immunomodulatory biologics

21. Fatty acid binding proteins shape the cellular response to activation of the glucocorticoid receptor

23. Trovafloxacin-Induced Liver Injury: Lack in Regulation of Inflammation by Inhibition of Nucleotide Release and Neutrophil Movement

24. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models

25. The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro

26. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models

27. Optimizing drug discovery by Investigative Toxicology: Current and future trends

28. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models

30. Optimizing drug discovery by Investigative Toxicology: Current and future trends

31. Optimizing drug discovery by Investigative Toxicology: Current and future trends

32. Trovafloxacin-Induced Liver Injury: Lack in Regulation of Inflammation by Inhibition of Nucleotide Release and Neutrophil Movement

33. Tissue influx of neutrophils and monocytes is delayed during development of trovafloxacin-induced tumor necrosis factor-dependent liver injury in mice

34. The expression of cytochrome P-450, epoxide hydrolase, and glutathione S-transferase in hepatocellular carcinoma

36. Trovafloxacin-Induced Liver Injury: Lack in Regulation of Inflammation by Inhibition of Nucleotide Release and Neutrophil Movement

37. Tissue influx of neutrophils and monocytes is delayed during development of trovafloxacin-induced tumor necrosis factor-dependent liver injury in mice

40. Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury

41. Identification and characterization of a naïve CD8+ T cell repertoire for benzylpenicillin.

42. Today's Challenges to De-Risk and Predict Drug Safety in Human "Mind-the-Gap".

43. Stem cell–derived models to improve mechanistic understanding and prediction of human drug‐induced liver injury

44. A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity

45. Key Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation Plans

46. Mechanism-Based Markers of Drug-Induced Liver Injury to Improve the Physiological Relevance and Predictivity of In Vitro Models

47. Comparative Proteomic Characterization of 4 Human Liver-Derived Single Cell Culture Models Reveals Significant Variation in the Capacity for Drug Disposition, Bioactivation, and Detoxication

Catalog

Books, media, physical & digital resources